The construction of ANSTO's Mo-99 Manufacturing Facility and the co-located Waste Treatment Facility was made possible by $168.8 million in funding allocated from the Federal Government.
What is Mo-99?
Mo-99 is the radioisotope used by millions of people around the world in nuclear medicine procedures for the diagnosis of heart disease and other diseases.
Mo-99 gives off very small amounts of radiation that is picked up by gamma cameras, providing vital information for doctors seeking to understand how the body parts of patients are functioning.Find out more about Mo-99
Manufacturing Mo-99 in Australia
The Mo-99 Manufacturing Facility ensures the long-term sustainability of Mo-99 supply in Australia, and positions Australia to supply bulk Mo-99 globally.
A few weeks prior to commencing manufacture in 2019, ANSTO staff received a tour. Watch the video to take a unique behind-the-scenes look inside this facility.
Mo-99 Waste Treatment Facility
The ANSTO Synroc® Mo-99 Waste Treatment Facility is under construction close to the reactor and manufacturing facility. The plant will process and encapsulate liquid waste from nuclear medicine production using ANSTO's Synroc® technology.
ANSTO's Synroc® technology is an Australian innovation that delivers a permanent, safe and economical way of treating waste from past, current and future manufacture of nuclear medicine and other processes. One of its main benefits is that it significantly reduces the volume of nuclear by-products compared to other methods (such as encasement in cement), potentially saving organisations many millions of dollars in the safe storage and ultimate disposal of their waste.